Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour

Current Topics in Behavioral Neurosciences

Volumn 18, Issue , 2014, Pages 67-80

  Beurel, Eléonore ^a   Nemeroff, Charles B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Arginine vasopressin; Behaviour; Corticotropin releasing factor; Stress

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; GLUCOCORTICOID; INTERLEUKIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NELIVAPTAN; OXYTOCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; SMALL MOLECULE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROCORTIN; VASOPRESSIN V1 RECEPTOR;

AGGRESSION; ANXIETY; ARTICLE; BEHAVIORAL STRESS; CEREBROSPINAL FLUID; COPING BEHAVIOR; DEPRESSION; EARLY LIFE STRESS; FEAR; HUMAN; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MEMORY CONSOLIDATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARAVENTRICULAR THALAMIC NUCLEUS; PATERNAL BEHAVIOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR;

EID: 84922056319     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2014_306     Document Type: Article

References (117)

1. Aguilera G (1994) Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 15:321-350
2. Aguilera G, Rabadan-Diehl C (2000) Vasopressinergic regulation of the hypothalamic-pituitaryadrenal axis: implications for stress adaptation. Regul Pept 96:23-29
3. Alescio-Lautier B, Paban V, Soumireu-Mourat B (2000) Neuromodulation of memory in the hippocampus by vasopressin. Eur J Pharmacol 405:63-72
4. Antoni FA (1986a) Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr Rev 7:351-378
5. Antoni FA (1986b) Oxytocin receptors in rat adenohypophysis: evidence from radioligand binding studies. Endocrinology 119:2393-2395
6. Antoni FA (1993) Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14:76-122
7. Arima H, House SB, Gainer H, Aguilera G (2002) Neuronal activity is required for the circadian rhythm of vasopressin gene transcription in the suprachiasmatic nucleus in vitro. Endocrinology 143:4165-4171
8. Austin MC, Janosky JE, Murphy HA (2003) Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men. Mol Psychiatry 8:324-332
9. Banki CM, Karmacsi L, Bissette G, Nemeroff CB (1992) CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur neuropsychopharmacol 2:107-113 the journal of the European College of Neuropsychopharmacology
10. Bao AM, Swaab DF (2010) Corticotropin-releasing hormone and arginine vasopressin in depression focus on the human postmortem hypothalamus. Vitam Horm 82:339-365
11. Berridge CW, Dunn AJ (1989) CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice. Pharmacol Biochem Behav 34:517-519
12. Bilbo SD, Yirmiya R, Amat J, Paul ED, Watkins LR, Maier SF (2008) Bacterial infection early in life protects against stressor-induced depressive-like symptoms in adult rats. Psychoneuroendocrinology 33:261-269
13. Bosch OJ, Neumann ID (2010) Vasopressin released within the central amygdala promotes maternal aggression. Eur J Neurosci 31:883-891
14. Britton DR, Koob GF, Rivier J, Vale W (1982) Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci 31:363-367
15. Brothers SP, Wahlestedt C, Nemeroff CB (2012) Modulation of HPA axis function for treatment of mood disorders. In: Z Rankovic, M Bingham, EJ Nestler, R Hargreaves (eds) RSC drug discovery series no. 28, drug discovery for psychiatric disorders, The royal society of chemistry 2012
16. Caffe AR, van Leeuwen FW, Luiten PG (1987) Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus. J Comp Neurol 261:237-252
17. Caldwell HK, Lee HJ, Macbeth AH, Young WS 3rd (2008) Vasopressin: behavioral roles of an ''original'' neuropeptide. Prog Neurobiol 84:1-24
18. Chadio SE, Antoni FA (1989) Characterization of oxytocin receptors in rat adenohypophysis using a radioiodinated receptor antagonist peptide. J Endocrinol 122:465-470
19. Champagne DL, Bagot RC, van Hasselt F, Ramakers G, Meaney MJ, de Kloet ER, Joels M, Krugers H (2008) Maternal care and hippocampal plasticity: evidence for experiencedependent structural plasticity, altered synaptic functioning, and differential responsiveness to glucocorticoids and stress. J Neurosci 28:6037-6045
20. Chen J, Aguilera G (2010) Vasopressin protects hippocampal neurones in culture against nutrient deprivation or glutamate-induced apoptosis. J Neuroendocrinol 22:1072-1081
21. Chen J, Liu Y, Soh JW, Aguilera G (2009) Antiapoptotic effects of vasopressin in the neuronal cell line H32 involve protein kinase Calpha and beta. J Neurochem 110:1310-1320
22. Chen J, Young S, Subburaju S, Sheppard J, Kiss A, Atkinson H, Wood S, Lightman S, Serradeil-Le Gal C, Aguilera G (2008) Vasopressin does not mediate hypersensitivity of the hypothalamic pituitary adrenal axis during chronic stress. Ann N Y Acad Sci 1148:349-359
23. Chen Y, Bender RA, Frotscher M, Baram TZ (2001) Novel and transient populations of corticotropin-releasing hormone-expressing neurons in developing hippocampus suggest unique functional roles: a quantitative spatiotemporal analysis. J Neurosci 21:7171-7181
24. Chen Y, Brunson KL, Adelmann G, Bender RA, Frotscher M, Baram TZ (2004) Hippocampal corticotropin releasing hormone: pre-and postsynaptic location and release by stress. Neuroscience 126:533-540
25. Chen Y, Brunson KL, Muller MB, Cariaga W, Baram TZ (2000) Immunocytochemical distribution of corticotropin-releasing hormone receptor type-1 [CRF(1)]-like immunoreactivity in the mouse brain: light microscopy analysis using an antibody directed against the C-terminus. J Comp Neurol 420:305-323
26. Collins SM, Surette M, Bercik P (2012) The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 10:735-742
27. Dayas CV, Buller KM, Crane JW, Xu Y, Day TA (2001) Stressor categorization: acute physical and psychological stressors elicit distinctive recruitment patterns in the amygdala and in medullary noradrenergic cell groups. Eur J Neurosci 14:1143-1152
28. De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA (1993) Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am j psychiatry 150:656-657
29. de Wied D, Diamant M, Fodor M (1993) Central nervous system effects of the neurohypophyseal hormones and related peptides. Front Neuroendocrinol 14:251-302
30. Dinan TG, Cryan JF (2012) Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology 37:1369-1378
31. Dinan TG, Scott LV (2005) Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J Anat 207:259-264
32. Donaldson ZR, Young LJ (2008) Oxytocin, vasopressin, and the neurogenetics of sociality. Science 322:900-904
33. Dunn AJ, Berridge CW, Lai YI, Yachabach TL (1987) CRF-induced excessive grooming behavior in rats and mice. Peptides 8:841-844
34. Ferguson JN, Young LJ, Insel TR (2002) The neuroendocrine basis of social recognition. Front Neuroendocrinol 23:200-224
35. Frank E, Landgraf R (2008) The vasopressin system-from antidiuresis to psychopathology. Eur J Pharmacol 583:226-242
36. Gillies GE, Linton EA, Lowry PJ (1982) Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299:355-357
37. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002) Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stressrelated disorders. Proc Nat Acad Sci USA 99:6370-6375
38. Griffante C, Green A, Curcuruto O, Haslam CP, Dickinson BA, Arban R (2005) Selectivity of d(Cha4)AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br J Pharmacol 146:744-751
39. Grigoriadis DE (2005) The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 9:651-684
40. Guastella AJ, Kenyon AR, Alvares GA, Carson DS, Hickie IB (2010) Intranasal arginine vasopressin enhances the encoding of happy and angry faces in humans. Biol Psychiatry 67:1220-1222
41. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM (2003) International union of pharmacology XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 55:21-26
42. Heim C, Newport DJ, Miller AH, Nemeroff CB (2000) Long-term neuroendocrine effects of childhood maltreatment. JAMA J Am Med Assoc 284:2321
43. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB (2008) The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 33:693-710
44. Heinrichs SC, Britton KT, Koob GF (1991) Both conditioned taste preference and aversion induced by corticotropin-releasing factor. Pharmacol Biochem Behav 40:717-721
45. Herman JP, Cullinan WE (1997) Neurocircuitry of stress: central control of the hypothalamopituitary-adrenocortical axis. Trends Neurosci 20:78-84
46. Heuser I, Bissette G, Dettling M, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Nemeroff CB, Holsboer F (1998) Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress Anxiety 8:71-79
47. Hodgson RA, Higgins GA, Guthrie DH, Lu SX, Pond AJ, Mullins DE, Guzzi MF, Parker EM, Varty GB (2007) Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 86:431-440
48. Holsboer F, Gerken A, Steiger A, Benkert O, Müller OA, Stalla GK (1984) Corticotropinreleasing-factor induced pituitary-adrenal response in depression. Lancet 1:55
49. Holsboer F, Ising M (2008) Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583:350-357
50. Huber D, Veinante P, Stoop R (2005) Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308:245-248
51. Iijima M, Chaki S (2007) An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog Neuropsychopharmacol Biol Psychiatry 31:622-627
52. Ising M, Zimmermann US, Kunzel HE, Uhr M, Foster AC, Learned-Coughlin SM, Holsboer F, Grigoriadis DE (2007) High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 32:1941-1949
53. Jaferi A, Bhatnagar S (2007) Corticotropin-releasing hormone receptors in the medial prefrontal cortex regulate hypothalamic-pituitary-adrenal activity and anxiety-related behavior regardless of prior stress experience. Brain Res 1186:212-223
54. Jard S, Barberis C, Audigier S, Tribollet E (1987) Neurohypophyseal hormone receptor systems in brain and periphery. Prog Brain Res 72:173-187
55. Joels M, Baram TZ (2009) The neuro-symphony of stress. Nat Rev Neurosci 10:459-466
56. Kalsbeek A, Fliers E, Hofman MA, Swaab DF, Buijs RM (2010) Vasopressin and the output of the hypothalamic biological clock. J Neuroendocrinol 22:362-372
57. Keck ME, Welt T, Muller MB, Uhr M, Ohl F, Wigger A, Toschi N, Holsboer F, Landgraf R (2003) Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 28:235-243
58. Korosi A, Baram TZ (2008) The central corticotropin releasing factor system during development and adulthood. Eur J Pharmacol 583:204-214
59. Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A (2012) Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 92:1813-1864
60. Kunzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, Ising M, Holsboer F (2003) Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37:525-533
61. Landgraf R (2006) The involvement of the vasopressin system in stress-related disorders. CNS Neurol Disord Drug Targets 5:167-179
62. Li JD, Burton KJ, Zhang C, Hu SB, Zhou QY (2009) Vasopressin receptor V1a regulates circadian rhythms of locomotor activity and expression of clock-controlled genes in the suprachiasmatic nuclei. Am J Physiol Regul Integr Comp Physiol 296:R824-R830
63. Lightman SL (2008) The neuroendocrinology of stress: a never ending story. J Neuroendocrinol 20:880-884
64. Lim MM, Young LJ (2004) Vasopressin-dependent neural circuits underlying pair bond formation in the monogamous prairie vole. Neuroscience 125:35-45
65. Litvin Y, Murakami G, Pfaff DW (2011) Effects of chronic social defeat on behavioral and neural correlates of sociality: vasopressin, oxytocin and the vasopressinergic V1b receptor. Physiol Behav 103:393-403
66. Ma XM, Levy A, Lightman SL (1997) Emergence of an isolated arginine vasopressin (AVP) response to stress after repeated restraint: a study of both AVP and corticotropin-releasing hormone messenger ribonucleic acid (RNA) and heteronuclear RNA. Endocrinology 138:4351-4357
67. Mak P, Broussard C, Vacy K, Broadbear JH (2012) Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat. J psychopharmacol 26:532-542
68. Maras PM, Baram TZ (2012) Sculpting the hippocampus from within: stress, spines, and CRH. Trends Neurosci 35:315-324
69. McCall C, Singer T (2012) The animal and human neuroendocrinology of social cognition, motivation and behavior. Nat Neurosci 15:681-688
70. McEwen BS (1998) Stress, adaptation, and disease: allostasis and allostatic load. Ann N Y Acad Sci 840:33-44
71. McEwen BS (2007) Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87:873-904
72. Meewisse ML, Reitsma JB, de Vries GJ, Gersons BP, Olff M (2007) Cortisol and post-traumatic stress disorder in adults: systematic review and meta-analysis. Br j psychiatry 191:387-392
73. Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Anisman H (2004) Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 24:1478-1485
74. Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, Kormann MS, Droste SK, Kuhn R, Reul JM et al (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6:1100-1107
75. Murgatroyd C, Wu Y, Bockmuhl Y, Spengler D (2010) Genes learn from stress: how infantile trauma programs us for depression. Epigenetics 5(3)
76. Nederhof E, Schmidt MV (2012) Mismatch or cumulative stress: toward an integrated hypothesis of programming effects. Physiol Behav 106:691-700
77. Nemeroff CB, Bissette G, Akil H, FinkM(1991) Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy: corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158:59-63
78. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988) Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45:577-579
79. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W (1984) Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226:1342-1344
80. Neumann ID, Landgraf R (2012) Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 35:649-659
81. Nickel T, Sonntag A, Schill J, Zobel AW, Ackl N, Brunnauer A, Murck H, Ising M, Yassouridis A, Steiger A et al (2003) Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 23:155-168
82. Overstreet DH, Griebel G (2005) Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the flinders sensitive line rat. Pharmacol Biochem Behav 82:223-227
83. Owens MJ, Overstreet DH, Knight DL, Rezvani AH, Ritchie JC, Bissette G, Janowsky DS, Nemeroff CB (1991) Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity. Neuropsychopharmacol 4:87-93
84. Pacak K, Palkovits M (2001) Stressor specificity of central neuroendocrine responses: implications for stress-related disorders. Endocr Rev 22:502-548
85. Pitkow LJ, Sharer CA, Ren X, Insel TR, Terwilliger EF, Young LJ (2001) Facilitation of affiliation and pair-bond formation by vasopressin receptor gene transfer into the ventral forebrain of a monogamous vole. J Neurosci 21:7392-7396
86. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF (1994) Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60:436-444
87. Ring RH (2005) The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr Pharm Des 11:205-225
88. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, Blackett KN, Sitthiamorn C, Sato H, Yusuf S (2004) Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 364:953-962
89. Ryckmans T (2010) Modulation of the vasopressin system for the treatment of CNS diseases. Curr Opin Drug Discov Devel 13:538-547
90. Samson WK, Schell DA (1995) Oxytocin and the anterior pituitary gland. Adv Exp Med Biol 395:355-364
91. Sawchenko PE, Imaki T, Potter E, Kovacs K, Imaki J, Vale W (1993) The functional neuroanatomy of corticotropin-releasing factor. In: Ciba Foundation symposium, vol 172, pp 5-21, discussion 21-29
92. Schmidt MV (2011) Animal models for depression and the mismatch hypothesis of disease. Psychoneuroendocrinology 36:330-338
93. Schmidt MV, Scharf SH, Sterlemann V, Ganea K, Liebl C, Holsboer F, Muller MB (2010) High susceptibility to chronic social stress is associated with a depression-like phenotype. Psychoneuroendocrinology 35:635-643
94. Shalev I, Israel S, Uzefovsky F, Gritsenko I, Kaitz M, Ebstein RP (2011) Vasopressin needs an audience: neuropeptide elicited stress responses are contingent upon perceived social evaluative threats. Horm Behav 60:121-127
95. Shimazaki T, Iijima M, Chaki S (2006) The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats. Eur J Pharmacol 543:63-67
96. Simon NG, Guillon C, Fabio K, Heindel ND, Lu SF, Miller M, Ferris CF, Brownstein MJ, Garripa C, Koppel GA (2008) Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Pat CNS Drug Discovery 3:77-93
97. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA et al (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102
98. Steckler T, Holsboer F (1999) Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry 46:1480-1508
99. Stedenfeld KA, Clinton SM, Kerman IA, Akil H, Watson SJ, Sved AF (2011) Novelty-seeking behavior predicts vulnerability in a rodent model of depression. Physiol Behav 103:210-216
100. Stemmelin J, Lukovic L, Salome N, Griebel G (2005) Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology 30:35-42
101. Stetler C, Miller GE (2011) Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med 73:114-126
102. Sutton RE, Koob GF, Le Moal M, Rivier J, Vale W (1982) Corticotropin releasing factor produces behavioural activation in rats. Nature 297:331-333
103. Swanson LW, Sawchenko PE, Rivier J, Vale WW (1983) Organization of ovine corticotropinreleasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36:165-186
104. Thompson RR, George K, Walton JC, Orr SP, Benson J (2006) Sex-specific influences of vasopressin on human social communication. Proc Natl Acad Sci USA 103:7889-7894
105. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19:162-166
106. Urani A, Philbert J, Cohen C, Griebel G (2011) The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice. Pharmacol Biochem Behav 98:425-431
107. van Gaalen MM, Stenzel-Poore MP, Holsboer F, Steckler T (2002) Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci 15:2007-2015
108. Veenema AH, Blume A, Niederle D, Buwalda B, Neumann ID (2006) Effects of early life stress on adult male aggression and hypothalamic vasopressin and serotonin. Eur J Neurosci 24:1711-1720
109. Veenema AH, Reber SO, Selch S, Obermeier F, Neumann ID (2008) Early life stress enhances the vulnerability to chronic psychosocial stress and experimental colitis in adult mice. Endocrinology 149:2727-2736
110. Veith RC, Lewis N, Langohr JI, Murburg MM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Bissette G, Nemeroff CB et al (1993) Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res 46:1-8
111. Wang SS, Kamphuis W, Huitinga I, Zhou JN, Swaab DF (2008) Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry 13:786-799
112. Wang Z, Ferris CF, De Vries GJ (1994). Role of septal vasopressin innervation in paternal behavior in prairie voles (Microtus ochrogaster). Proc Nat Acad Sci USA 91:400-404
113. Winslow JT, Hastings N, Carter CS, Harbaugh CR, Insel TR (1993) A role for central vasopressin in pair bonding in monogamous prairie voles. Nature 365:545-548
114. Yehuda R, Golier JA, Kaufman S (2005) Circadian rhythm of salivary cortisol in holocaust survivors with and without PTSD. Am J Psychiatry 162:998-1000
115. Zhao L, Brinton RD (2004) Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: a cAMP response element-binding protein-dependent mechanism. J Neurosci 24:2226-2235
116. Zink CF, Stein JL, Kempf L, Hakimi S, Meyer-Lindenberg A (2010) Vasopressin modulates medial prefrontal cortex-amygdala circuitry during emotion processing in humans. J Neurosci 30:7017-7022
117. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181